Tutorials: Oct 1, 2010 (Vol. 30, No. 17)

Improving Assays for Micronuclei Detection

Application of High-Content Analysis System Can Be Beneficial in Toxicity Screening

(Page 1 of 3)

    The induction of micronuclei is a key characteristic of genotoxic compounds; for example, clastrogens produce DNA strand breakage while aneugens interfere with chromosome segregation. As a result, assays that detect micronuclei have become an important component of toxicology screening for new drug candidates.

    Traditionally, micronucleus screening was performed manually by highly skilled technicians using optical microscopy and cell counting; with this time-consuming method, however, analysis was subject to operator variance, bias, and error. An improved alternative is now provided with GE Healthcare’s IN Cell Analyzer 2000 high-content analysis system. The sub-cellular resolution of the system enables micronuclei to be easily discerned, while the automated software provides faster analysis and consistent objective scoring.

    Guidelines for in vitro micronucleus assays used in genotoxicity testing usually recommend scoring at least 2,000 cells per treatment condition for single samples, or at least 1,000 cells per condition if replicate assays are used. Therefore, a critical factor in establishing robust high-content cell assays is the assurance that sufficient cells are imaged per treatment condition.

    This is attained on IN Cell Analyzer 2000 by automatically counting cells “online” as each image is acquired. In this optional acquisition mode, successive fields of view are acquired until a preset cell-count threshold is achieved.

    Online cell counting has the additional advantage of reducing plate read times and the data-storage burden as no excess images are acquired once the required number of cells has been imaged.

    Table 1. Plate acquisition times achieved for 96-well micronuclei formation dose-response assays
    Click To Enlarge +

    Table 1. Plate acquisition times achieved for 96-well micronuclei formation dose-response assays

    Variable Cell Counts

    For the purposes of this tutorial, CHO-K1 cells were seeded onto 96-well Matriplate microplates and incubated with mitomycin C (clastogen) or etoposide (aneugen) for 48 hours to induce micronuclei formation. The cells were fixed with ethanol and stained with FITC and Hoechst 33342. With the online cell-count threshold set to 1,000 cells/well, plates were imaged on IN Cell Analyzer 2000 with the 20x/0.45 NA objective.

    The improved performance of the online cell-counting feature in variable cell-count assays is illustrated (Table 1) compared to results obtained using an offline analysis protocol. For mononucleated micronucleus assays configured with multiple replicates per treatment condition, a minimum cell count of 1,000 cells/well is recommended.

    Without online cell counting, 34 fields of view needed to be acquired from each well to ensure a sufficient cell count was achieved (based on the maximum field count obtained when online cell counting was applied).

    This resulted in a plate acquisition time of 80 minutes with the standard-chip camera, compared to an acquistion time of 37 minutes when online cell counting was applied under comparable conditions. As summarized in Table 1, the use of online cell counting significantly decreased the plate acquisition times for the assay.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

BLOG biotech

Webinars

GEN Podcasts

Video Channel

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll